Deutsche Bank Kept Okta (OKTA) As “Buy”; Has TP Of $85; Chemocentryx (CCXI) Sentiment Is 0.93

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Chemocentryx Inc (CCXI) investors sentiment decreased to 0.93 in 2018 Q4. It’s down -0.05, from 0.98 in 2018Q3. The ratio has worsened, as 42 hedge funds increased or started new stock positions, while 45 sold and decreased positions in Chemocentryx Inc. The hedge funds in our database now possess: 27.13 million shares, up from 26.80 million shares in 2018Q3. Also, the number of hedge funds holding Chemocentryx Inc in top ten stock positions was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 38 Increased: 24 New Position: 18.

In a note revealed on Friday morning, Okta Inc (OKTA) stock “Buy” was restate by Deutsche Bank. They currently have a $85 PT on the stock. Deutsche Bank’s PT would indicate a potential upside of 4.53% from the company’s previous stock close.

Okta, Inc. operates an integrated system that connects persons via devices. The company has market cap of $8.98 billion. The company’s identity cloud connects various companies to pre-integrated apps and devices every day. It currently has negative earnings. It offers single sign-on, mobility management, adaptive multi-factor authentication, lifecycle management, and universal directory products for IT customers; and complete authentication, user management, flexible administration, API access management, and developer tools for developers.

More notable recent Okta, Inc. (NASDAQ:OKTA) news were published by: Nasdaq.com which released: “What to Expect From Okta Stock Going Into Earnings – Nasdaq” on March 06, 2019, also Nasdaq.com with their article: “OKTA Stock: What Has OKTA Down Today? – Nasdaq” published on March 04, 2019, Seekingalpha.com published: “Okta -9% on larger net loss forecast – Seeking Alpha” on March 07, 2019. More interesting news about Okta, Inc. (NASDAQ:OKTA) were released by: Seekingalpha.com and their article: “Switch To Calls Going Into Okta Earnings Season – Seeking Alpha” published on February 12, 2019 as well as Nasdaq.com‘s news article titled: “After-Hours Earnings Report for March 7, 2019 : COST, MRVL, OKTA, KFY, OEC, NVEE, NSTG, UPLD, AOBC, LOCO, QTRX, UMH – Nasdaq” with publication date: March 07, 2019.

The stock increased 3.69% or $2.89 during the last trading session, reaching $81.32. About 1.85 million shares traded. Okta, Inc. (OKTA) has risen 118.57% since March 11, 2018 and is uptrending. It has outperformed by 114.20% the S&P500. Some Historical OKTA News: 23/05/2018 – Facebook is starting to take the enterprise world seriously, and its new partner, identity management service Okta, can provide much-needed credibility; 22/04/2018 – DJ Okta Inc Class A, Inst Holders, 1Q 2018 (OKTA); 23/05/2018 – VMWARE INC – CO, OKTA ANNOUNCED A PARTNERSHIP AND INTEGRATION BETWEEN VMWARE WORKSPACE ONE AND OKTA IDENTITY CLOUD; 23/05/2018 – Zylo Kicks SaaS Optimization into High Gear for Okta Customers; 23/05/2018 – Facebook wants to be taken seriously in the workplace and is counting on Okta for help; 07/03/2018 – OKTA INC – SEES FY NON-GAAP NET LOSS PER SHARE OF $0.67 TO $0.62,; 07/03/2018 – OKTA 4Q ADJ LOSS/SHR 10C, EST. LOSS/SHR 14C; 15/05/2018 – Okta Presenting at JPMorgan Conference Tomorrow; 18/05/2018 – Okta to Webcast Oktane18; 07/03/2018 – OKTA 4Q REV. $77.8M, PRELIM. $77M-$77.5M

Among 11 analysts covering Okta (OKTA), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Okta has $90 highest and $62 lowest target. $78.56’s average target is -3.39% below currents $81.32 stock price. Okta had 13 analyst reports since October 18, 2018 according to SRatingsIntel. The stock has “Sector Weight” rating by KeyBanc Capital Markets on Monday, February 4. The firm earned “Buy” rating on Friday, March 8 by Deutsche Bank. Canaccord Genuity maintained Okta, Inc. (NASDAQ:OKTA) rating on Friday, March 8. Canaccord Genuity has “Buy” rating and $85 target. The rating was maintained by Oppenheimer with “Buy” on Friday, March 8. The stock of Okta, Inc. (NASDAQ:OKTA) earned “Buy” rating by FBN Securities on Friday, March 8. The stock has “Hold” rating by SunTrust on Monday, March 4.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” on February 26, 2019, also Benzinga.com with their article: “Benzinga’s Top Upgrades, Downgrades For February 11, 2019 – Benzinga” published on February 11, 2019, Seekingalpha.com published: “ChemoCentryx terminates previously announced common stock offering – Seeking Alpha” on September 28, 2018. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Seekingalpha.com and their article: “ChemoCentryx withdraws conditional approval application for avacopan in Europe – Seeking Alpha” published on January 24, 2019 as well as Globenewswire.com‘s news article titled: “ChemoCentryx Announces Proposed Public Offering of Common Stock – GlobeNewswire” with publication date: September 26, 2018.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $515.87 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 41.34 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

The stock increased 2.00% or $0.2 during the last trading session, reaching $10.21. About 79,392 shares traded. ChemoCentryx, Inc. (CCXI) has risen 12.22% since March 11, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13

Since January 1, 0001, it had 0 buys, and 8 insider sales for $87.64 million activity.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *